Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $58.00 and last traded at $58.00, with a volume of 1503 shares trading hands. The stock had previously closed at $55.39.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Jefferies Financial Group lifted their target price on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Wedbush boosted their target price on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Truist Financial increased their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $67.63.

Dianthus Therapeutics Stock Down 1.0%

The stock has a market cap of $2.66 billion, a P/E ratio of -17.65 and a beta of 1.56. The business’s 50-day simple moving average is $47.95 and its two-hundred day simple moving average is $40.22.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DNTH. Fairmount Funds Management LLC raised its holdings in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after acquiring an additional 600,000 shares during the period. Vestal Point Capital LP grew its position in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC lifted its holdings in Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.